Effective targeted therapies suffer from the development of resistance and often severe toxicity. Our novel platform technology delays resistance with a mild side affects.
OUR TECHNOLOGY
Targeting the ‘fuel’ that feeds cancer
With our novel platform technology, we develop synthetic molecules that induce natural antibodies to remove growth factors active in cancer
IMPROVING EXISTING THERAPEUTICS
Augmenting existing approved therapeutics.
First clinical trial has confirmed extending progression free survival without adding toxicity
MULTIPLE TARGETS
Addressing multiple growth factors in cancer pathways
The platform technology can produce mono specific ( single target ) and bi-specific ( multi target ) molecules that target different pathways and address different solid tumours.
HOW ARE WE DIFFERENT?
Mechanism of action – the molecules we produce
Our approach works in the extracellular matrix, by triggering B cells response to produce specific antibodies to neutralize the targeted growth factors. Removal of specific growth factors involved in cancer signalling prevent uncontrolled proliferation.
Data from studies suggest that this approach is less toxic than other approved treatments, making our therapeutics well tolerated with a mild toxicity profile when compared to other leading immune-therapies approach in the market.